Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
05 December 2024
| Name: | FARMAFORCE LIMITED (FFC) |
| ISIN: | AU000000FFC7 |
| Date of Listing: | 27 October 2015 |
| Date of Delisting: | 29 August 2022 |
Stock Exchange Status:
This entity was delisted from the Australian Securities Exchange on 29 August 2022.Legal Status:
ACN: 167 748 843ABN: 95 167 748 843
Registration Date: 28 January 2014
Capital Gains Tax (CGT) Status:
This entity is in liquidation, its securities in our opinion, are of little or no value. Previously listed entities that enter external administration, rarely provide a distribution to shareholders unless the winding up is for reasons other than corporate failure. If you are still a holder of securities and seek to realise a capital loss for Capital Gains Tax (CGT) purposes you will need to wait until the liquidator has issued a declaration of loss (a CGT Event) or the entity is deregistered (a CGT Event) or the entity recovers. (Once an entity “progresses” to the liquidation stage, deListed is unable to acquire its securities.).
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
REGISTRY:
Boardroom Pty Ltd
Level 8, 210 George Street, Sydney NSW 2000
Tel : +61 2 9290 9600 or 1300 737 760
Fax : +61 2 9279 0664 or 1300 653 459
RegistryWebsite RegistryEmail
company is now called A.C.N. 167 748 843 LIMITED | 05/11/2023 |
delisted following failure to pay the annual ASX listing fees per Listing Rule 17.15 | 29/08/2022 |
we understand the company failed to pay to ASX Limited the annual listing fees for the year ending 30 June 2023 | 29/08/2022 |
Under Listing Rule 17.6, an entity (if not already suspended) that had not paid its annual listing fees by close of business on Friday, 19 August 2022 would have its securities suspended from Official Quotation before the commencement of trading on Monday, 22 August 2022. The following entity has failed to pay to ASX Limited the annual listing fees for the year ending 30 June 2023, and each entity's securities are already suspended from quotation. Under Listing Rule 17.15, any entity that has not paid its annual listing fees as required by Listing Rule 16.5 by 5.00 pm AEST on Friday, 26 August 2022 will be removed from the Official List with effect from the close of trading on Friday, 26 August 2022. | 22/08/2022 |
Mark Robinson, Antony Resnick and Riad Tayeh were appointed Joint and Several Administrators of the above company on 10 March 2022. On 11 July 2022 creditors resolved to place the company into liquidation. The likelihood of a return to shareholders is remote and depends primarily on the total amount of creditors' claims and our investigations into the Company's financial affairs. | 29/07/2022 |
this company, now in liquidation, is called ACN 167 748 843 - apparently the company's business was sold around the same time a change of company name occurred - (3 June 2022 - courtesy of AFR "Arrotex Pharmaceuticals, backed by AFR Rich Lister Dennis Bastas, has snapped up Farmaforce from the administrators of failed controversial biotech iQ Group Global. The administrators at De Vries Tayeh also confirmed that offers had been made for a yacht that the biotechnology outfit had bought for $1.2 million.") | 19/07/2022 |
Mark Robinson and Anthony Resnick of de Vries Tayeh are appointed liquidators | 11/07/2022 |
The company has entered voluntary administration with the directors appointing Mark Robinson, Anthony Resnick, and Riad Tayeh of de Vries Tayeh as joint and several voluntary administrators. | 11/03/2022 |
The audit review of its half-year report for the six months ended 31 December 2021 has not yet been completed. The Company is working with its auditor to complete the review and the Company expects to release its audited halfyear report on Monday 7 March 2022. | 01/03/2022 |
The company's securities will be suspended from official quotation from the commencement of trading today, 1 March 2022, following its failure to lodge the relevant periodic report by the due date. | 01/03/2022 |
listed entity carried for record purposes only | 27/10/2015 |
company is now called A.C.N. 167 748 843 LIMITED | 05/11/2023 |
delisted following failure to pay the annual ASX listing fees per Listing Rule 17.15 | 29/08/2022 |
we understand the company failed to pay to ASX Limited the annual listing fees for the year ending 30 June 2023 | 29/08/2022 |
Under Listing Rule 17.6, an entity (if not already suspended) that had not paid its annual listing fees by close of business on Friday, 19 August 2022 would have its securities suspended from Official Quotation before the commencement of trading on Monday, 22 August 2022. The following entity has failed to pay to ASX Limited the annual listing fees for the year ending 30 June 2023, and each entity's securities are already suspended from quotation. Under Listing Rule 17.15, any entity that has not paid its annual listing fees as required by Listing Rule 16.5 by 5.00 pm AEST on Friday, 26 August 2022 will be removed from the Official List with effect from the close of trading on Friday, 26 August 2022. | 22/08/2022 |
Mark Robinson, Antony Resnick and Riad Tayeh were appointed Joint and Several Administrators of the above company on 10 March 2022. On 11 July 2022 creditors resolved to place the company into liquidation. The likelihood of a return to shareholders is remote and depends primarily on the total amount of creditors' claims and our investigations into the Company's financial affairs. | 29/07/2022 |
this company, now in liquidation, is called ACN 167 748 843 - apparently the company's business was sold around the same time a change of company name occurred - (3 June 2022 - courtesy of AFR "Arrotex Pharmaceuticals, backed by AFR Rich Lister Dennis Bastas, has snapped up Farmaforce from the administrators of failed controversial biotech iQ Group Global. The administrators at De Vries Tayeh also confirmed that offers had been made for a yacht that the biotechnology outfit had bought for $1.2 million.") | 19/07/2022 |
Mark Robinson and Anthony Resnick of de Vries Tayeh are appointed liquidators | 11/07/2022 |
The company has entered voluntary administration with the directors appointing Mark Robinson, Anthony Resnick, and Riad Tayeh of de Vries Tayeh as joint and several voluntary administrators. | 11/03/2022 |
The audit review of its half-year report for the six months ended 31 December 2021 has not yet been completed. The Company is working with its auditor to complete the review and the Company expects to release its audited halfyear report on Monday 7 March 2022. | 01/03/2022 |
The company's securities will be suspended from official quotation from the commencement of trading today, 1 March 2022, following its failure to lodge the relevant periodic report by the due date. | 01/03/2022 |
listed entity carried for record purposes only | 27/10/2015 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NATURE | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|---|
| 12/12/2020 | Con Tsigounis | 220,000 | $0.085 | $18,700 | |
| 11/12/2020 | George Elias | 220,000 | $0.085 | $18,700 | |
| 11/12/2020 | Harry Simeonidis | 108,471 | $0.085 | $9,220 | |
| 11/12/2020 | Con Tsigounis | 220,000 | $0.085 | $18,700 | |
| 30/11/2020 | Harry Simeonidis | 55,800 | $0.085 | $4,743 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Vincenzo Milazzo | Non Exec Chairman | 17/06/2021 |
| Terence Rego | Non Exec Director | 22/03/2021 |
| Con Tsigounis | Director | 24/06/2015 |
| Kosmas Dimitriou | Company Secretary |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| George Syrmalis | Non Exec Director | 24/11/2015 | 23/11/2021 |
| Harry Simeonidis | Executive Director | 14/08/2017 | 30/08/2021 |
| George Elias | Non Exec Chairman | 04/04/2015 | 17/06/2021 |
| Stamatia Tolias | Independent Director | 02/04/2015 | 14/08/2017 |
| Daniel Morato | Executive Director | 07/04/2015 | 23/11/2015 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2024 Investogain Pty Limited. All rights reserved.
